Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 1009-1016

  Ford, Jennifer ^a   Boffito, Marta ^b   Maitland, Desmond ^b   Hil, Andrew ^a   Back, David ^a   Khoo, Saye ^a   Nelson, Mark ^b   Moyle, Graeme ^b   Gazzard, Brian ^b   Pozniak, Anton ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antivirals; Intracellular pharmacokinetics; Protease inhibitors

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ATAZANAVIR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; OLIGOPEPTIDE; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; RITONAVIR; SAQUINAVIR; TUMOR PROTEIN;

ADULT; ARTICLE; BLOOD; DOSE RESPONSE; DRUG INTERACTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LYMPHOCYTE; MALE; METABOLISM; MIDDLE AGED;

ADULT; ATP-BINDING CASSETTE TRANSPORTERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OLIGOPEPTIDES; P-GLYCOPROTEIN; PYRIDINES; RITONAVIR; SAQUINAVIR;

EID: 37849040586     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl379     Document Type: Article

References (33)

1. Haas DW, Zala C, Schrader S et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative pilot trial. AIDS 2003; 17: 1339-49.
2. Sanne I, Piliero P, Squires K et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32: 18-29.
3. Colonno RJ, Thiry A, Limoli K et al. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003; 47: 1324-33.
4. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-91.
5. Aarnoutse RE, Wasmuth JC, Fatkenheuer G et al. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antivir Ther 2003; 8: 309-14.
6. van Heeswijk RP, Veldkamp AI, Hoetelmans RM et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13: F95-9.
7. Cooper CL, van Heeswijk RP, Gallicano K et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003; 36: 1585-92.
8. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105-13.
9. Boffito M, Kurowski M, Kruse G et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291-7.
10. Winston A, Mallon P, Satchell C et al. The pharmacokinetic profile and safety of saquinavir-ritonavir administered once daily with atazanavir or twice daily with a nucleoside backbone using the saquinavir-500 mg formulation in HIV-1 infected subjects. Seventh International Workshop on Clinical Pharmacology of HIV Therapy, 2006, Abstract 64.
11. Hoetelmans RM. Sanctuary sites in HIV-1 infection. Antivir Ther 1998; 3 Suppl 4: 13-7.
12. Hoggard PG, Owen A. The mechanisms that control intracellular penetration of the HIV protease inhibitors. J Antimicrob Chemother 2003; 51: 493-6.
13. Klimecki WT, Futscher BW, Grogan TM et al. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-8.
14. Malomi W, Lucia MB, Rainaldi G et al. Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. Haematologica 1998; 83: 13-20.
15. Lee CG, Gottesman MM, Cardarelli CO et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594-601.
16. Washington CB, Duran GE, Man MC et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 203-9.
17. Kim RB. Drug transporters in HIV Therapy. Top HIV Med 2003; 11 136-9.
18. Jones K, Hoggard PG, Sales SD et al. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001; 15: 675-81.
19. Meaden ER, Hoggard PG, Newton P et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002; 50: 583-8.
20. Boffito M, Maitland D, Dickinson L et al. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV type 1-infected individuals administered different atazanavir doses. AIDS Res Hum Retroviruses 2006; 22: 749-56.
21. Meaden ER, Hoggard PG, Khoo SH et al. Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods 2002; 262: 159-65.
22. Ford J, Boffito M, Wildfire A et al. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2388-93.
23. Khoo SH, Hoggard PG, Williams I et al. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother 2002; 46: 3228-35.
24. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
25. Gao WY, Cara A, Gallo RC et al. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993; 90: 8925-8.
26. Khoo SH, Hennessy M, Mulcahy F et al. Differences in intracellular drug accumulation between protease inhibitors. Eighth Conference on Retroviruses and Opportunistic Infections, 2001. Abstract 258.
27. von Hentig NH, Mueller A, Haberl A et al. The ATSAQ-1 cohort study: Pharmacokinetic interactions of atazanavir (AZV) and saquinavir (SQV) in a ritonavir (RTV) boosted protease inhibitor therapy regimen. Fifteenth International AIDS Conference, 2004. Abstract WeOrB1235.
28. Kashuba AD, Dyer JR, Kramer LM et al. Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43: 1817-26.
29. Peytavin G, Landman R, Lamotte C et al. Saquinavir (SQV) plasma and intracellular concentrations in a once daily dosing combination FORTOVASE (SQV SGC)-low dose ritonavir (RTV) in a prospective study (IMEA 015) in HIV-infected patients (pts). Second International Workshop of Clinical Pharmacology of HIV Therapy, 2001, Abstract 3.16.
30. Gieschke R, Fotteler B, Buss N et al. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet 1999; 37: 75-86.
31. Autar RS, Ananworanich J, Apateerapong W et al. Pharmacokinetic (PK) study of saquinavir hard gel caps/ritonavir (SQV-HGC/RTV) in HIV-1 infected patients: 1600/100 mg OD compared to 2000/100 mg OD and 1000/ 100 mg BID. Ninth European Conference on Clinical Aspects and Treatment of HIV-Infection, 2003, Abstract 4.1/1.
32. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999; 13: 1623-7.
33. Shiraki N, Hamada A, Yasuda K et al. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. Biol Pharm Bull 2000; 23: 1528-31.